The Globe and Mail

Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance and Accelerates Recurring Revenue Growth Across AI and Dermatology

EBITDA guidance raised by €4.5M as Cosmo executes on its Vision 2030 strategy; H1 Recurring Revenues from GI Genius™ up 128%, Winlevi® up 23%; Investors Call today at 2 pm CET. Dublin, ...
InfoQ

New Azure Cosmos DB Features to Boost Performance and Optimize Cost

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...
Yahoo Finance

Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Cosmo Pharmaceuticals' (VTX:COPN) stock up by 2.3% over the past three months. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance. In this ...
Finanznachrichten

Cosmo Pharmaceuticals N.V.: Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance and Accelerates Recurring Revenue Growth Across AI and Dermatology

EBITDA guidance raised by €4.5M as Cosmo executes on its Vision 2030 strategy; H1 Recurring Revenues from GI Genius up 128%, Winlevi® up 23%; Investors Call today at 2 pm CET. Dublin, ...